Dr. Bosse on Challenges With Immunotherapy in Pediatric Cancers

Video

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Bosse says that choosing the correct immunotherapy for pediatric patients with solid tumors is a challenge. There are some immunotherapies in the pipeline being developed to target certain molecules in neuroblastoma, but finding targets has proven difficult.

As a result of the success of chimeric antigen receptor T-cell therapy, CD19 has become the gold standard, Bosse says. There are very few other molecules like that on pediatric cancers, posing a challenge in developing new cellular therapies and immunotherapeutics.

Cancers are very apt to developing resistance mechanisms to potent therapies by losing antigens or switching lineage, which can allow them to hide, Bosse explains. Combination therapies, or dual-targeting immunotherapeutics may be an approach to overcome this, he suggests.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,